Volume 74, Issue 3 pp. 1203-1219
Original Article

Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer

Elizabeth P. Newberry

Elizabeth P. Newberry

Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA

Search for more papers by this author
Zoe Hall

Zoe Hall

Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, Cambridge, United Kingdom

Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Biomolecular Medicine, Imperial College London, London, United Kingdom

Search for more papers by this author
Yan Xie

Yan Xie

Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA

Search for more papers by this author
Elizabeth A. Molitor

Elizabeth A. Molitor

Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA

Search for more papers by this author
Peter O. Bayguinov

Peter O. Bayguinov

Washington University Center for Cellular Imaging, St. Louis, MO, USA

Search for more papers by this author
Gregory W. Strout

Gregory W. Strout

Washington University Center for Cellular Imaging, St. Louis, MO, USA

Search for more papers by this author
James A.J. Fitzpatrick

James A.J. Fitzpatrick

Washington University Center for Cellular Imaging, St. Louis, MO, USA

Departments of Cell Biology & Physiology and Neuroscience, Washington University School of Medicine, St. Louis, MO, USA

Department of Biomedical Engineering, Washington University in Saint Louis, St. Louis, MO, USA

Search for more papers by this author
Elizabeth M. Brunt

Elizabeth M. Brunt

Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA

Search for more papers by this author
Julian L. Griffin

Julian L. Griffin

Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, Cambridge, United Kingdom

Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Biomolecular Medicine, Imperial College London, London, United Kingdom

Search for more papers by this author
Nicholas O. Davidson

Corresponding Author

Nicholas O. Davidson

Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA

ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:

Nicholas O. Davidson, M.D., D.Sc.

Gastroenterology Division, Washington University School of Medicine

660 S. Euclid Avenue, St. Louis, MO 63110

E-mail: [email protected]

Tel: +1-(314) 362-2027

Search for more papers by this author
First published: 27 February 2021
Citations: 14
Supported by grants from the Medical Research Council (MC UP A90 1006 and MC PC 13030); National Institutes of Health (DK-119437 and DK-112378); Washington University Digestive Diseases Research Core Center (P30 DK-52574); the Washington University Center for Cellular Imaging, which is funded in part by Washington University School of Medicine; the Children’s Discovery Institute of Washington University and St. Louis Children’s Hospital (CDI-CORE-2015-505 and CDI-CORE-2019-813); the Foundation for Barnes-Jewish Hospital (3770); the Washington University Diabetes Research Center (DK020579); the Washington University Rheumatic Diseases Research Resource-Based Center (AR073752); and Siteman Cancer Center of Barnes-Jewish Hospital and Washington University School of Medicine (CA091842).
Potential conflict of interest: Nothing to report.

Abstract

Background and Aims

Human transmembrane 6 superfamily 2 (TM6SF2) variant rs58542926 is associated with NAFLD and HCC. However, conflicting reports in germline Tm6sf2 knockout mice suggest no change or decreased very low density lipoprotein (VLDL) secretion and either unchanged or increased hepatic steatosis, with no increased fibrosis. We generated liver-specific Tm6Sf2 knockout mice (Tm6 LKO) to study VLDL secretion and the impact on development and progression of NAFLD.

Approach and Results

Two independent lines of Tm6 LKO mice exhibited spontaneous hepatic steatosis. Targeted lipidomic analyses showed increased triglyceride species whose distribution and abundance phenocopied findings in mice with liver-specific deletion of microsomal triglyceride transfer protein. The VLDL triglyceride secretion was reduced with small, underlipidated particles and unchanged or increased apolipoprotein B. Liver-specific adeno-associated viral, serotype 8 (AAV8) rescue using either wild-type or mutant E167K-Tm6 reduced hepatic steatosis and improved VLDL secretion. The Tm6 LKO mice fed a high milk-fat diet for 3 weeks exhibited increased steatosis and fibrosis, and those phenotypes were further exacerbated when mice were fed fibrogenic, high fat/fructose diets for 20 weeks. In two models of HCC, either neonatal mice injected with streptozotocin (NASH/STAM) and high-fat fed or with diethylnitrosamine injection plus fibrogenic diet feeding, Tm6 LKO mice exhibited increased steatosis, greater tumor burden, and increased tumor area versus Tm6 flox controls. Additionally, diethylnitrosamine-injected and fibrogenic diet–fed Tm6 LKO mice administered wild-type Tm6 or E167K-mutant Tm6 AAV8 revealed significant tumor attenuation, with tumor burden inversely correlated with Tm6 protein levels.

Conclusions

Liver-specific Tm6sf2 deletion impairs VLDL secretion, promoting hepatic steatosis, fibrosis, and accelerated development of HCC, which was mitigated with AAV8- mediated rescue.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.